Healthcare / Diagnostics & ResearchTaipei Exchange
$8.70
-0.30 (-3.35%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-111.8M · quality 31.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$439M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.2%
↓Gross Margin
28.2%
↓Debt/Equity
2.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.3%
FCF CAGR
—
FCF margin
-38.2%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $199.9M · net income $-73.0M · FCF $-76.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $199.9M | $199.9M | $116.5M | $132.7M | $133.8M |
| Net Income | $-73.0M | $-73.0M | $-82.9M | $-72.6M | $-42.7M |
| EBITDA | $-32.8M | $-32.8M | $-46.8M | $-41.9M | $-22.7M |
| EPS | — | — | -1.64 | -1.60 | -0.98 |
| Gross Margin | 28.2% | 28.2% | 35.6% | 32.1% | 33.4% |
| Operating Margin | -28.3% | -28.3% | -69.7% | -44.5% | -32.8% |
| Net Margin | -36.5% | -36.5% | -71.1% | -54.7% | -31.9% |
| Balance Sheet | |||||
| Debt/Equity | 2.35 | 2.35 | 1.77 | 1.29 | 0.03 |
| Current Ratio | 1.58 | 1.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-76.4M | $-76.4M | $-111.8M | $-745.3M | $-34.0M |
| Returns | |||||
| ROE | -26.2% | -26.2% | -23.7% | -16.4% | -12.6% |
| Valuation | |||||
| P/B | 1.58 | 1.58 | 1.92 | 2.12 | 2.63 |
| Growth & Yield | |||||
| Revenue Growth | 71.5% | 71.5% | -12.2% | -0.8% | — |
| EPS Growth | — | — | -2.5% | -63.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.64 → n/d
Residual
-28.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.